FY2024 EPS Estimates for Acelyrin Increased by HC Wainwright

Acelyrin, Inc. (NASDAQ:SLRN) – Research analysts at HC Wainwright boosted their FY2024 earnings per share estimates for shares of Acelyrin in a research note issued to investors on Thursday, November 14th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($2.43) per share for the year, up from their previous estimate of ($3.35). HC Wainwright has a “Neutral” rating and a $8.00 price target on the stock. The consensus estimate for Acelyrin’s current full-year earnings is ($2.90) per share. HC Wainwright also issued estimates for Acelyrin’s Q4 2024 earnings at ($0.72) EPS, FY2025 earnings at ($2.17) EPS, FY2026 earnings at ($2.56) EPS, FY2027 earnings at ($2.07) EPS and FY2028 earnings at ($1.30) EPS.

A number of other research firms also recently weighed in on SLRN. Morgan Stanley cut their price target on Acelyrin from $13.00 to $6.00 and set an “equal weight” rating for the company in a research note on Monday, August 19th. Piper Sandler cut their price target on Acelyrin from $68.00 to $20.00 and set an “overweight” rating for the company in a research note on Wednesday, August 14th. Finally, Wells Fargo & Company raised their price target on Acelyrin from $13.00 to $15.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 16th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.50.

Acelyrin Trading Down 0.9 %

Shares of Acelyrin stock opened at $4.65 on Monday. The stock has a 50-day moving average price of $5.41 and a 200 day moving average price of $5.03. The company has a market cap of $466.52 million, a P/E ratio of -1.91 and a beta of 1.98. Acelyrin has a 1 year low of $3.36 and a 1 year high of $9.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Acelyrin by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 6,237,543 shares of the company’s stock valued at $42,103,000 after acquiring an additional 81,633 shares during the last quarter. Millennium Management LLC increased its position in Acelyrin by 15.7% in the 2nd quarter. Millennium Management LLC now owns 4,642,056 shares of the company’s stock worth $20,471,000 after buying an additional 628,528 shares during the period. Blue Owl Capital Holdings LP lifted its holdings in shares of Acelyrin by 3.5% during the second quarter. Blue Owl Capital Holdings LP now owns 2,926,028 shares of the company’s stock worth $12,904,000 after buying an additional 100,000 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Acelyrin by 30.8% during the third quarter. Geode Capital Management LLC now owns 1,651,614 shares of the company’s stock worth $8,144,000 after buying an additional 388,631 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Acelyrin by 10.0% in the third quarter. State Street Corp now owns 1,273,096 shares of the company’s stock valued at $6,276,000 after acquiring an additional 116,094 shares during the period. Institutional investors and hedge funds own 87.31% of the company’s stock.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.